By 2024, Molecular Diagnostics Market in Europe to hit $3.3 Bn : Grapghical Research - PowerPoint PPT Presentation

About This Presentation

By 2024, Molecular Diagnostics Market in Europe to hit $3.3 Bn : Grapghical Research


Graphical Research has reported the addition of the “Molecular Diagnostics Market: Europe Industry Analysis and Opportunity Assessment 2018 - 2024" report to their offering. – PowerPoint PPT presentation

Number of Views:41


Transcript and Presenter's Notes

Title: By 2024, Molecular Diagnostics Market in Europe to hit $3.3 Bn : Grapghical Research

Molecular Diagnostics - Europe Market to Hit 3.3
Bn by 2024 Graphical Research
According to the Graphical Research new growth
forecast report titled "Europe Molecular
Diagnostics Market Size By Technology (PCR, In
Situ Hybridization, Chips And Microarrays, Mass
Spectrometry, Sequencing, Isothermal
Amplification), By Application (Infectious
Disease, Blood Screening, Genetic Testing,
Oncology Testing), Industry Report, Growth
Analysis Forecast, 2018 - 2024", estimated to
exceed USD 3.3 Billion By 2024.
2013 2014 2015 2016 2017 2018
2019 2020 2021 2022 2023 2024
Infectious disease Blood screening Genetic
besting Oncology testing
Rising demand for point of care diagnostics
coupled with favorable RD initiatives will drive
Europe molecular diagnostics market growth.
According to Future Medicine journal, till now
around USD 3.6 billion has been capitalized in
personalized medicine research across the medical
innovation cycle. Moreover, rising demand for
personalized medicines in Europe should boost
business growth over the coming years. Request
for a sample of this report _at_ https//www.graphica Technological
advancements in PCR and DNA sequencing methods
will foster Europe molecular diagnostics industry
growth over the forecast timeframe. Government
initiatives to support development of molecular
diagnostics platform will positively impact
business growth. For instance, the European
Alliance for Personalized Medicine (EAPM) held
conference on November 2017, that focused on
opportunities aimed at health services and
therapies for patients. Additionally, the
European Personalized Medicine Association is
scheduling to fund grants in tutoring and
training of future healthcare experts with
emphasis of using diagnostics and patient
engagement positioned on personalized medicine.
Blood screening segment will grow at 8.1 over
the forecast timeframe due to growing incidence
of blood cancers and essential blood cancer
diagnosis should propel industry growth. As per
CDC data in the U.S. nearly 47,135 individuals
were diagnosed with leukemia in 2014 that
comprised of around 19,646 women and 27,489
men. Isothermal amplification technology segment
accounted for 16.9 revenue share in 2017, as a
result of recent acknowledgement of proteins that
has assisted novel in vitro isothermal DNA
amplification techniques growth, that mimics in
vivo mechanisms. Furthermore, isothermal
amplification is widely used for analysis and
detection of tiny amounts of nucleic acids
thereby, should propel segmental growth over the
forecast timeline. Browse key industry insights
from this Report _at_ https//www.graphicalresearch.c
UK molecular diagnostics market was valued at USD
156.7 in 2017 due to increasing RD coupled with
presence of sophisticated healthcare
infrastructure and higher disposable income.
Moreover, growth in personalized therapy as well
as diagnostics sector should result in
opportunities for molecular diagnostics business
growth over the coming years. Some of the
prominent business competitors operating in the
Europe molecular diagnostics market include
Abbott Molecular, Agilent (Dako), Alere, Analytik
Jena, Becton Dickinson, Biomerieux, BioRad
Laboratories, Danaher, Johnson Johnson, Roche
Diagnostics and others. Major business players
adopt strategies such as collaborations, novel
product launch, mergers and acquisitions to
sustain their position in the industry. For
instance, in October 2017, Roche's cobas Zika
test used along with cobas 6800/8800 systems
received U.S. FDA approval. The approval of cobas
Zika test expands company's product portfolio for
screening blood-borne diseases. Make an Inquiry
for purchasing this Report _at_ https//www.graphical
Segments we cover Europe Molecular Diagnostics
Market Statistics, By Application Infectious
disease o Flu o RSV virus o Tuberculosis o
Meningitis o HIV market o Hepatitis C o Hepatitis
o HPV o STD o Dengue o H. pylori o TORCH o
Others Blood screening Genetic
testing Oncology testing Europe Molecular
Diagnostics Market Growth, By Technology
PCR In situ hybridization Chips and
microarrays Mass spectrometry
Sequencing Isothermal amplification
Browse Table of Contents _at_ https//www.graphicalre
diagnostics-market About Graphical Research
Graphical Research is a business research firm
that provides industry insights, market forecast
and strategic inputs through granular research
reports and advisory services. We publish
targeted research reports with an aim to address
varied customer needs, from market penetration
and entry strategies to portfolio management and
strategic outlook. We understand that business
requirements are unique our syndicate reports
are designed to ensure relevance for industry
participants across the value chain. We also
provide custom reports that are tailored to the
exact needs of the customer, with dedicated
analyst support across the purchase
lifecycle. Contact Us Parikhit B. Corporate
sales, Graphical Research Email Web
Write a Comment
User Comments (0)